Recently, a role for a functional polymorphism within the promoter region of the serotonin transporter gene (5-HTTLPR) in conferring susceptibility to Obsessive Compulsive Disorder (OCD) has been suggested. The aim of this study was to test the hypothesis that allelic variation of the 5-HTTLPR could be associated with OCD susceptibility or influence the drug response in OCD. One hundred and eighty-one OCD patients were recruited; 92 patients underwent a standardized treatment with fluvoxamine. No significant differences in allele/genotype distribution of the 5-HTTLPR were found between 191 controls and OCD. No differences in fluvoxamine response in the three genotypes groups in OCD were found, considering Yale-Brown Obsessive Compulsive Scale (YBOCS) total scores. Nevertheless, a significant time per genotype interaction was found for the YBOCS subtotal compulsion scores. Considering patients without tic disorder co-diagnosis, a significant time per genotype interaction for both YBOCS total scores and compulsion scores was found
INTRODUCTION
A great deal of evidence, coming from familial, twin and segregation studies, suggests that a genetic component underlies Obsessive-Compulsive Disorder (OCD). [1] [2] [3] [4] [5] [6] Nevertheless, molecular genetic studies failed to individuate genes with minor or major effect in the susceptibility to OCD, 7, 8 or reported contrasting results. [9] [10] [11] [12] This could be due to the paucity of genes studied to date. In fact, all published studies have considered some structures in the serotonergic and/or dopaminergic system (receptor and/or transporter proteins). To date there are no published genome scan data, which could be of help in choosing good candidate genes involved in the etiopathogenesis of OCD. 13 The implication of the serotonin (5-HT) system in the pathophysiology of OCD is supported by different avenues of research, including peripheral markers of 5-HT function, data about drug responses and pharmacological challenge probes. 14 Serotonin Reuptake Inhibitors (SRIs), both non-selective (clomipramine) and selective (SSRIs; ie fluvoxamine) have been proven to be effective in the pharmacological treatment of OCD. 15 These drugs have in common a potent inhibition of serotonin reuptake. Fluvoxamine, one of the most powerful SSRIs, is reported to be an effective treatment for OCD. 16 On the other hand, a considerable proportion of OC patients (ranging from 40 to 60%) fails to respond to these drugs. 17 Serotonin transporter (5-HTT) protein determines the reuptake of serotonin from the intersynaptic cleft, representing the prime target for SRIs. A 44-bp deletion/insertion functional polymorphism within the promoter region of the serotonin transporter gene (5-HTTLPR) leads in vitro to different transcriptional rates of 5-HTT protein. 18 The basal transcriptional activity of the long variant (l allele) is more than twice that of the short form (s allele) and differences in 5-HTT mRNA synthesis result in different 5-HTT expression and 5-HT cellular uptake. 19 Since the 5-HTT is the primary target of action for SRIs, it is possible to hypothesize that allelic variation of 5-HTTLPR could be an important factor in conferring susceptibility to OCD, and also influence the individual response to these drugs, as in mood disorders. Different studies report that ll homozygotes show a more prompt 20 and better antidepressant response than ls and ss individuals. 21, 22 On the contrary, a Korean study by Kim et al reports a better antidepressant response in ss homozygotes, while they report that allelic variation of a VNTR (Variable Number of Tandem Repeats) in intron 2 of the gene coding for the 5-HTT may affect the antidepressant response to SSRI drugs. 23 Billet et al 9 failed to find an association between OCD and 5-HTTLPR, while Bengel et al 11 found an increased number of ll genotypes in OCD patients when compared to controls, replicating the results of a family-based association study. 10 Billet et al 9 failed also to find an association between SRIs response and OCD patients, with a retrospective rating of the patients' clinical response to SRIs.
The aim of our work is to study the distribution of the 5-HTTLPR in an Italian population of OCD patients and to test the hypothesis that allelic variation of 5-HTT gene expression is linked to antiobsessional response to fluvoxamine.
RESULTS
Genotype and allele frequencies of 5-HTTLPR for the casecontrol study are shown in Table 1 . The genotypic distribution was not significantly different from the distribution expected according to Hardy-Weinberg equilibrium in OCD patients ( 2 ϭ 0.083 with 1 df and P ϭ 0.772) and in the control group ( 2 ϭ 0.435 with 1 df and P ϭ 0.509). No differences were found in the genotypic or allelic distribution between OCD patients and healthy controls ( 2 ϭ 2.254, 1 df, P ϭ 0.133 for alleles, 2 ϭ 2.961, 2 df, P ϭ 0.228 for genotypes).
Genotype frequencies as well as clinical and demographic characteristics of the sample included in the fluvoxamine treatment group are shown in Table 2 . No significant differences were observed among genotype groups. Fluvoxamine plasma levels (ng ml
Ϫ1
) did not significantly differ among genotype groups (mean Ϯ SD: ll ϭ 267.66 Ϯ 228.68; ls ϭ Homogeneity of variances at outset was successfully tested for YBOCS scores. The rate of affective disorder and panic disorder co-diagnosis in the OCD sample was 13.5% and 12.5%, respectively. Coexisting diagnoses were not significantly related to antiobsessional response as computed by ANOVAR, with co-diagnoses as grouping factors (data not shown).
A two-way repeated measures analysis of variance on total YBOCS scores showed no significant differences according to genotypes (Figure 1 ), while a time effect was observed (F(1,85) ϭ 160.06, P ϭ 0.000).
Considering YBOCS compulsion scores, we observed a time effect (F(1,85) ϭ 143.29, P ϭ 0.000) and a significant time per genotype interaction (F[2,85] ϭ 3.73, P ϭ 0.0281), while considering YBOCS obsession scores a significant time effect (F(1,85) ϭ 132.91, P ϭ 0.000) but no time per genotype interaction was observed.
OCD patients with TD co-diagnosis may have a poor response to SRI treatment, while they improve after addition of dopamine blockers to SRI. 24 This evidence suggests that OCD plus TD may represent a subgroup of patients with a different etiologic liability. Analysis of 79 patients without TD co-diagnosis showed a significant effect for time per 5-HTTLPR genotype interaction in conditioning response to fluvoxamine treatment (F (2,76) ϭ 3.33, P ϭ 0.041). Moreover, considering YBOCS compulsion scores in patients without TD, significant effects of time (F(1,76) ϭ 132.22, P ϭ 0.00) and time per genotype (F(2,76) ϭ 5.2, P ϭ 0.0077) interaction were observed (Figure 2 ), while only a time effect is present in the case of YBOCS obsession scores (F(1,76) ϭ 118.02, P ϭ 0.00). OCD patients with TD diagnosis are too few to perform a separate analysis on them.
DISCUSSION
In the case of complex disorders, such as psychiatric disorders, association studies results are often negative or inconclusive. One of the possible explanations relies on the multifactorial etiopatogenesis of OCD. In fact, we can hypothesize that a polymorphic gene could influence only a small part of the phenotypic variance. Therefore, one experimental approach could be the selection of specific clinical features to subdivide patients into homogeneous subgroups and to perform association studies between genes and these subphenotypes. Drug response could be an important feature to classify patients; it is well known that as many as 40-60% of OCD patients may not respond to an adequate treatment with an SSRI. 16, 25 Defining the treat- ment response as a reduction of the YBOCS total scores Ͼ 35%, our sample shows a response rate of 56.6%, which is in accord with the literature's data. Nevertheless, using the 35% YBOCS reduction for defining a responder patient, even though useful in clinical practice, could be not adequate for a genetic approach.
In our prospective study we therefore decided to correlate 5-HTTLPR genotypes with the YBOCS scores variation during the pharmacological treatment; this allows for a more conservative description of the response. Treatment response may be under genetic control, 26 and much evidence supports the hypothesis of a possible influence of 5-HTTLPR in conditioning pharmacological response to SSRIs in OCD. This has already been shown in the case of mood disorders: several studies show an association between the 5-HTTLPR ll genotype and a better and earlier response to
The Pharmacogenomics Journal different SSRIs. [20] [21] [22] Moreover 5-HTTLPR seems also to be associated with the prophylactic efficacy of lithium in mood disorders. 27 Our data do not seem to correlate the different 5-HTTLPR genotypes with YBOCS total score variation. Our findings seem therefore to be in accord with those of the retrospective study of Billet et al, 9 who tested the association between treatment response to different SRIs and 5-HTTLPR.
It has to be considered that the severity scoring of YBOCS includes multiple parameters: time spent, interference, anxiety, resistance and control of obsessions and compulsions. These different clinical dimensions may have a differential response to drug treatment. Furthermore, obsessions and compulsions may vary in a different way after drug treatment. In fact, analyzing separately the variation of obsessions and compulsions subtotal scores after fluvoxamine treatment, we found a significant time per 5-HTTLPR genotype interaction for compulsions only.
Another aspect to consider is the clinical heterogeneity of OCD. Clinical features such as TD co-diagnosis can select a subgroup of patients who respond to the association of SRIs and neuroleptics. 24 Moreover, a significant (50%) proportion of refractory OCD patients with and without TD are responders to risperidone augmentation therapy. 28 These data, as well as neuroanatomical models, suggest a possible interactive role of serotonin and dopamine at least in a subgroup of OCD patients. 29 Considering OCD patients without TD co-diagnosis, we observed a significant time per 5-HTTLPR genotype interaction, which is due to greater reduction in compulsion scores (contrast analysis: ls Ͼ ss, F ϭ 9.081, 1 df, P ϭ 0.003564 and ls Ͼ ll, F ϭ 4.4187, 1 df, P ϭ 0.039044) after 12 weeks treatment.
5-HTTLPR genotypes seem not to influence directly the drug response, but rather to act as a modifying agent in conditioning it. It is in fact possible to hypothesize that drug response is a multifactorial phenotype, whose expression can be determined by several factors linked to different neurotransmitter systems.
Our findings seem to highlight a different mechanism of action in the response to SSRIs treatment between OCD and affective disorders. Even if SRIs are efficacious in the OCD treatment, clinical evidence suggests a different way of response for affective disorder and OCD. In fact, the anti-OCD effect of SRIs generally requires a much longer delay than the antidepressant effect 30 and higher doses of SRIs are frequently necessary to obtain a clinical effect. 31, 32 Blier and de Montigny 33 proposed a detailed discussion about biological mechanisms underlying the differences between the antidepressant and antiobsessive responses. In particular much evidence indicates that the anti-OCD effect, unlike the antidepressant response, is based on the inhibition of the 5-HT reuptake process. Neuroimaging, neuropsychological and neurophysiological studies in humans have suggested that a neuronal loop connecting the orbitofrontalcingulate cortex to basal ganglia could be involved in the pathophysiology of OCD. 29 The brain region involved in the pathophysiology of the disorder appears therefore to be different from that involved in depression, such as the hippocampus or the hypothalamus. 33 Moreover, effective augmentation strategies (eg pindolol) appear to be different in the two disorders, suggesting different pathophysiological mechanisms. 33 It has been described that it may take as long as 10-12 weeks for OCD patients to arrive at an initial response, and several months, or even longer to achieve a maximum response. 14 We cannot therefore exclude that the limited time of our observation could have influenced our findings.
The possibility that other polymorphisms in the gene coding for 5-HTT, such as the VNTR in intron 2, may be contributing to influencing drug response, cannot be discarded; therefore, the study of other polymorphisms in this gene could be of interest.
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In conclusion, we hypothesize that a fruitful approach to this problem could be to study the role of gene coding for different neurotransmitter systems (such as serotonin and dopamine) structures and their possible interactions, in relation to drug response. Moreover, given the possible heterogeneity of phenotypes, it could be more appropriate to correlate genetic variation with more homogeneous clinical subgroups.
MATERIALS AND METHODS

Subjects and Treatment
A sample of 181 patients (88 females, 93 males; mean age ϭ 33.37 Ϯ 11.49 yrs; mean age at onset ϭ 18.03 Ϯ 8.81 yrs), fulfilling DSM-IV 34 diagnostic criteria for OCD were included in the case-control study. All subjects have been evaluated, to confirm or exclude diagnosis, by means of the Italian version of the Diagnostic Interview Schedule-Revised (DIS-R). 35 Data were scored by a computer program and then modified according to DSM-IV criteria where appropriate.
Within the total sample, 92 patients were assigned to and concluded a 12-week standardized treatment with fluvoxamine (200-300 mg day Ϫ1 ). 25 Enrollment criteria are extensively reported in the paper by Erzegovesi et al. 25 No concomitant therapy was allowed during the whole treatment period, either pharmacological or non-pharmacological. As for non-pharmacological therapy, no form of psychotherapy was allowed (eg, exposure to response prevention or cognitive therapy).
Patients were sequentially admitted to the Anxiety Disorder Clinic and Research Unit at San Raffaele University Hospital, Milan. On admission, diagnoses and family histories were assessed by senior psychiatrists. Severity of obsessive-compulsive symptoms, before and after treatment, scored on the Yale Brown Obsessive-Compulsive Scale (YBOCS), 36 were assessed by trained raters blind to genotyping. All probands were investigated for presence/absence of chronic motor Tic Disorder (TD) and for presence/absence of positive family history for OCD and TD in first degree relatives, assessed according to the Family History (FH-RDC) method. 37 One hundred and ninety-one healthy controls, closely questioned by an experienced psychiatrist by means of DIS-R 35 to exclude any psychiatric disorder and with a negative family history for psychiatric disorders according to FH-RDC, were recruited among department personnel (104 females and 87 males; mean actual age 35.27 Ϯ 8.55 years). Written and oral informed consent was obtained from all subjects, who were all unrelated and of Italian descent.
Data Collection
According to data from previous literature, 38, 39 response to treatment was defined as a reduction of YBOCS total score of at least 35% between the score at the beginning of the treatment (T o ) and the score after 12 weeks of treatment (T 12 ) with fluvoxamine.
In order to obtain a more homogeneous sample, plasma levels of fluvoxamine for the patients were determined at the fourth week of treatment (after 2 weeks of stable therapy) by high-performance liquid chromatography as previously described. 40 Four patients with fluvoxamine plasma levels exceeding the mean value of the sample Ϯ 1.96 SD were excluded from the study, to avoid extreme differences in the bioavailability of the drug influencing the clinical response. 21 Genomic DNA was extracted from whole blood of patients and healthy controls. Target DNA was amplified by polymerase chain reaction and detected as previously described. 41 Genotyping was performed blind to the clinical status condition or to the outcome of the drug therapy.
Statistical Analysis
Comparisons of genotypic and allelic frequencies between OCD patients and controls were performed by chi-square statistics.
Power analysis performed on our sample with an ␣ value of 0.05 and the frequency of the genotype at a risk of 37.7 revealed that our sample had a power of 80% to detect a minimum value of Odds Ratio of 1.77.
Baseline clinical and demographic characteristics of the OCD patients according to the genotype were compared with a one-way analysis of variance (ANOVA) on continuous variables and with chi-square statistics on dichotomous variables.
Changes in YBOCS scores over time were analyzed with a repeated measure analysis of variance (ANOVAR) with time as within subject factor, and genotype as between subjects factor.
Statistical analyses have been performed with Statistica package, version 6. 
